Total Payments
$1.6M
2024 Payments
$466,544
Companies
41
Transactions
1,381
Medicare Patients
382
Medicare Billing
$99,706
Payment Breakdown by Category
Other$1.1M (73.8%)
Travel$199,997 (12.9%)
Consulting$171,328 (11.0%)
Food & Beverage$35,414 (2.3%)
Education$505.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $993,341 | 274 | 63.9% |
| Travel and Lodging | $199,997 | 463 | 12.9% |
| Consulting Fee | $171,328 | 62 | 11.0% |
| Honoraria | $153,617 | 50 | 9.9% |
| Food and Beverage | $35,414 | 521 | 2.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,020 | 1 | 0.1% |
| Education | $505.75 | 10 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $295,799 | 178 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $273,984 | 243 | $0 (2024) |
| Blueprint Medicines Corporation | $161,997 | 182 | $0 (2024) |
| Astellas Pharma US Inc | $151,571 | 114 | $0 (2024) |
| Incyte Corporation | $110,769 | 128 | $0 (2024) |
| GlaxoSmithKline, LLC. | $75,492 | 47 | $0 (2024) |
| SOBI, INC | $73,038 | 36 | $0 (2024) |
| Celgene Corporation | $64,325 | 57 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $55,303 | 34 | $0 (2024) |
| Kite Pharma, Inc. | $50,260 | 48 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $466,544 | 398 | GlaxoSmithKline, LLC. ($64,656) |
| 2023 | $366,536 | 319 | E.R. Squibb & Sons, L.L.C. ($110,175) |
| 2022 | $422,385 | 352 | E.R. Squibb & Sons, L.L.C. ($124,763) |
| 2021 | $142,748 | 128 | Celgene Corporation ($42,797) |
| 2020 | $77,450 | 55 | Jazz Pharmaceuticals Inc. ($22,321) |
| 2019 | $62,436 | 71 | JAZZ PHARMACEUTICALS INC. ($25,271) |
| 2018 | $15,061 | 36 | Incyte Corporation ($6,483) |
| 2017 | $2,065 | 22 | Pharmacyclics LLC, An AbbVie Company ($1,105) |
All Payment Transactions
1,381 individual payment records from CMS Open Payments — Page 2 of 56
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,964.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $107.22 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $3,276.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $3,276.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,008.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,008.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $127.95 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/28/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| 11/27/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $46.61 | General |
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,260.00 | General |
| 11/19/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: Rare Disease | ||||||
| 11/18/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Travel and Lodging | In-kind items and services | $769.90 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/14/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $119.76 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Immunology | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | In-kind items and services | $394.97 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | In-kind items and services | $157.07 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $120.06 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,530.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | In-kind items and services | $1,449.25 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $32.21 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 137 | 397 | $107,705 | $34,053 |
| 2022 | 4 | 88 | 237 | $95,475 | $25,721 |
| 2021 | 4 | 98 | 270 | $115,800 | $29,032 |
| 2020 | 2 | 59 | 128 | $64,565 | $10,900 |
Total Patients
382
Total Services
1,032
Medicare Billing
$99,706
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 43 | 219 | $37,230 | $14,697 | 39.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 28 | 63 | $33,705 | $7,101 | 21.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 64 | $16,000 | $6,459 | 40.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 19 | $6,080 | $2,094 | 34.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $9,750 | $1,941 | 19.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 18 | 19 | $4,940 | $1,761 | 35.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 38 | 115 | $61,525 | $13,727 | 22.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 92 | $23,000 | $8,208 | 35.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 15 | $7,050 | $2,406 | 34.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 15 | 15 | $3,900 | $1,380 | 35.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 48 | 160 | $85,600 | $19,292 | 22.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 78 | $19,500 | $6,939 | 35.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 13 | 17 | $6,800 | $1,415 | 20.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 12 | 15 | $3,900 | $1,386 | 35.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 37 | 99 | $52,965 | $9,020 | 17.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 22 | 29 | $11,600 | $1,880 | 16.2% |
About George Yaghmour
George Yaghmour is a Hematology & Oncology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/20/2009. The National Provider Identifier (NPI) number assigned to this provider is 1669604849.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, George Yaghmour has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $466,544 received in 2024. These payments were reported across 1,381 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($993,341).
As a Medicare-enrolled provider, Yaghmour has provided services to 382 Medicare beneficiaries, totaling 1,032 services with total Medicare billing of $99,706. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Los Angeles, CA
- Active Since 08/20/2009
- Last Updated 11/16/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1669604849
Products in Payments
- VYXEOS (Drug) $211,066
- ONUREG (Drug) $210,739
- AYVAKIT (Drug) $158,032
- REBLOZYL (Biological) $127,082
- Xospata (Drug) $114,358
- JAKAFI (Drug) $100,406
- OJJAARA (Drug) $75,492
- Rezlidhia (Drug) $55,303
- GAMIFANT (Drug) $53,159
- DEFITELIO (Drug) $52,313
- Yescarta (Drug) $38,326
- ICLUSIG (Drug) $36,950
- XOSPATA (Drug) $33,897
- ELZONRIS (Drug) $32,179
- VENCLEXTA (Drug) $24,099
- Gamifant (Drug) $19,879
- COPIKTRA (Drug) $19,582
- TIBSOVO (Drug) $13,609
- SOLIRIS (Biological) $9,731
- ULTOMIRIS (Biological) $9,498
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Los Angeles
Dennis Slamon, Md, MD
Hematology & Oncology — Payments: $4.3M
Hematology & Oncology $4.3M
Dr. Robert Vescio, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Dr. Kevin Kelly, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
David Berz, Md, Phd, Mph, MD, PHD, MPH
Hematology & Oncology — Payments: $613,380
Hematology & Oncology $613,380
Raghuveer Ranganathan, M.d, M.D
Hematology & Oncology — Payments: $472,334
Hematology & Oncology $472,334
Antoni Ribas, Md, MD
Hematology & Oncology — Payments: $470,926
Hematology & Oncology $470,926